Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

Inclusion Criteria

• a) Primary Refractory Disease (defined as failure to achieve even a partial response to induction therapy) b) Consolidation of a partial remission (defined as a decrease but continued presence of monoclonal protein on serum and urine immunofixation electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and biopsy) c) Relapsing after prior therapy (disease relapsing after achieving a partial or complete response to prior conventional or high-dose therapy).
• Age up to 75 years.
• Zubrod performance status of 40%. No uncontrolled arrhythmias or symptomatic cardiac disease.
• Forced expiratory volume (FEV1), forced volume vital capacity (FVC) and Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) >40%. No symptomatic pulmonary disease.
• Serum bilirubin 1L prior to drainage.
• HIV-negative.
• Negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization
• Patient or guardian able to sign informed consent
• Corrected QT interval less than 470 msec.

Exclusion Criteria

• Corrected QT interval greater than 470 msec.
• Patients in complete remission (defined as the absence of monoclonal protein on serum and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone marrow aspirate and biopsy).
• Patients with non-secretory myeloma.